Neurocrine Biosciences, Inc. announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time ...

Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...

The American College of Medical Genetics and Genomics' (ACMG) celebration of this impactful healthcare specialty will unite the entire medical genetics ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.

Psilocybin significantly reduces confidence in negative self-beliefs four weeks after administration, with effects linked to ...

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Cognizant (Nasdaq: CTSH) announced an expanded agreement with Medidata, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, to provide support for ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...